Drug firm Dr Reddy's Laboratories said today the US health regulator has completed inspection of its Srikakulam facility without making any observations.
"The audit of our active pharmaceutical ingredient (API) Srikakulam Plant (SEZ), Andhra Pradesh, by the United States Food and Drug Administration (USFDA), has been completed today with no observations, Dr Reddy's Laboratories said in a filing to BSE.
The regulator issues Form 483 observations to a firm's management at the conclusion of an inspection to notify it of objectionable conditions at the facility.
As per USFDA, it is issued when investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Disclaimer: No Business Standard Journalist was involved in creation of this content
